Skip to main content

Research Repository

Advanced Search

An exploration of the direct biological targets of molecular hydrogen

Hancock, John; May, Jennifer E.; LeBaron, Tyler W.; Punampalam, Rajalakshmi; Russell, Grace

Authors

Profile image of John Hancock

John Hancock John.Hancock@uwe.ac.uk
Professor in Cell Signalling

Tyler W. LeBaron

Rajalakshmi Punampalam

Grace Russell



Contributors

Jan Slezak
Editor

Branislav Kura
Editor

Abstract

Molecular hydrogen (H2), supplied either as a gas or in a solution, has been gaining popularity as a treatment for a variety of conditions and diseases. For example, it has been suggested to be beneficial for neurodegenerative diseases, to ease the injuries caused by restoration of blood flow to previously ischaemic tissues, and even to alleviate the symptoms of COVID-19. It has also been suggested as an ergogenic sports supplement. However, the exact mode of action of H2 has yet to be definitively unravelled. It has been suggested that H2 acts as an antioxidant and, in particular, as a scavenger of hydroxyl radicals (•OH). This might be the case, but it is unlikely that this is the only mode of action of H2 in biological systems. Here we discuss some of the possible mechanisms by which H2 may have an effect, which may explain how it is acting in a medical context.

Online Publication Date Feb 17, 2024
Publication Date Feb 17, 2024
Deposit Date Oct 19, 2023
Publicly Available Date Feb 18, 2026
Publisher Springer
Pages 21-38
Series Title Advances in Biochemistry in Health and Disease
Book Title Molecular Hydrogen in Health and Disease
ISBN 9783031473746
DOI https://doi.org/10.1007/978-3-031-47375-3
Public URL https://uwe-repository.worktribe.com/output/11184503
Publisher URL https://link.springer.com/book/9783031473746
Additional Information Just been told about this by the editors who said they cite it as:
Slezak, J. & Kura, B. (In press, 2024). Molecular Hydrogen in Health and Disease. ISBN 978-3-031-47374-6. Springer Cham.
However, unlikely to be in the shops before early 2024
Contract Date Oct 18, 2023